{"commentary":{"count":57,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":19,"podcast":19,"x_thread":18,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04182204\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"POLARGO","nct_id":"NCT04182204","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=polargo-nct04182204. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"POLARGO","arms":[{"description":"Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m\\^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\\^2 administered IV and oxaliplatin 100 mg/m\\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.","label":"Pola-R-GemOx (Stage 1)","type":"EXPERIMENTAL"},{"description":"Participants will receive polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle administered IV and rituximab 375 mg/m\\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\\^2 administered IV and oxaliplatin 100 mg/m\\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.","label":"Pola-R-GemOx (Stage 2)","type":"EXPERIMENTAL"},{"description":"Participants will receive rituximab 375 mg/m\\^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m\\^2 administered IV and oxaliplatin 100 mg/m\\^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.","label":"R-GemOx (Stage 2)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-11-29","type":"ACTUAL"},"conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":{"count":270,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Polatuzumab Vedotin","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"}],"last_update":"2025-12-22","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Alone in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-11-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Stage 1: Number of Participants With Adverse Events (AEs)","timeFrame":"From treatment initiation until 90 days after the last dose of study drug or initiation of non-protocol-specified anti-lymphoma treatment (NALT) (Up to approximately 8.3 months)"},{"measure":"Stage 1: Number of Participants With Peripheral Neuropathy (PN)","timeFrame":"From treatment initiation until 90 days after the last dose of study drug or initiation of NALT (Up to approximately 8.3 months)"},{"measure":"Stage 2: Overall Survival (OS)","timeFrame":"From randomization to death (Up to approximately 34 months)"}],"references":[{"citation":"Matasar M, Li Z, Vassilakopoulos TP, Sancho JM, Viardot A, McMillan A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C. Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. J Clin Oncol. 2026 Sep;44(25):2435-2446. doi: 10.1200/JCO-25-02849. Epub 2026 Jul 6.","pmid":"42407012","type":"DERIVED"}],"start_date":{"date":"2020-02-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT04182204"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/polargo-nct04182204"}